ArticleScientific reports2025
Predicted peptide scaffolds for drug screening in endometrial cancer organoids.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Smart hydrogels for overcoming cancer multidrug resistance.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AlphaFold, a deep learning-based platform widely used to predict protein and peptide structures, was employed in this study to model the self-assembling peptide RFC, which demonstrated a stable α-helical structure with high confidence. This structural prediction was supported by experimental analyses, which revealed the peptide's ability to form dense fibrillar networks and robust hydrogels, particularly at higher concentrations. These hydrogels effectively supported the 3D culture of endometrial cancer organoids, which retained key tumor characteristics, including high proliferative activity and resistance to platinum-based drugs. Among tested therapeutics, Doxorubicin showed the strongest efficacy, significantly reducing organoid viability. This study highlights the predictive power of AlphaFold in elucidating peptide structures and guiding biomaterial development. The RFC hydrogel, combined with organoid modeling, represents a promising platform for advancing cancer research and precision medicine. These findings demonstrate the synergistic value of computational tools like AlphaFold and experimental approaches in creating innovative solutions for challenging biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.